Here is the press releast .Now the question is . W
Post# of 153768
(Total Views: 983)
Posted On: 06/28/2020 11:21:54 AM
Here is the press releast .Now the question is . When did Vyera get the stock from 4 million investment..So Vyera investment paid most if not all the in price continues up for the milestone .. Nice for them ..
Date Open High Low Close* Adj Close** Volume
Dec 27, 2019 0.83 1.05 0.82 0.98 0.98 8,268,900
Dec 26, 2019 0.64 0.79 0.62 0.78 0.78 4,641,500
Dec 24, 2019 0.61 0.66 0.58 0.64 0.64 1,772,600
Dec 23, 2019 0.62 0.67 0.58 0.61 0.61 4,180,600
Dec 20, 2019 0.65 0.66 0.50 0.58 0.58 5,232,900
Dec 19, 2019 0.43 0.74 0.43 0.63 0.63 9,052,700
Dec 18, 2019 0.35 0.45 0.35 0.42 0.42 3,501,500
Dec 17, 2019 0.29 0.31 0.29 0.30 0.30 443,700
Dec 16, 2019 0.31 0.31 0.29 0.29 0.29 647,700
December 17, 2019 16:36 ET | Source: CytoDyn, Inc.
In exchange for the exclusive right to market and distribute leronlimab in the U.S. for HIV-related indications, Vyera will pay upfront and regulatory and sales-based milestone payments of up to $87.5 million, as well as a royalty of 50 percent on net sales. Vyera will also make an investment in CytoDyn of $4 million in the form of registered CytoDyn common stock
CytoDyn will maintain responsibility for the development and FDA approval of leronlimab for all HIV-related and other indications
VANCOUVER, Washington and NEW YORK, Dec. 17, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn”) and Vyera Pharmaceuticals, LLC (“Vyera”), today announced that they have entered into a Commercialization and License Agreement (CLA) and a related Supply Agreement to commercialize leronlimab (PRO 140) in the U.S. for the treatment of HIV.
Under the terms of the CLA, CytoDyn will maintain responsibility for the development and FDA approval of leronlimab for all HIV-related and other indications, while Vyera has been granted an exclusive license to market and distribute leronlimab in the U.S. for the treatment of HIV. In exchange for such exclusive license, Vyera has agreed to pay upfront and regulatory and sales-based milestone payments of up to $87.5 million, as well as a royalty of 50 percent on net sales. Vyera also agreed to make an investment in CytoDyn of $4 million in the form of registered CytoDyn common stock.
It is anticipated that these agreements will enable CytoDyn to leverage Vyera’s well-established commercial infrastructure and highly-experienced sales team for the launch and commercialization of leronlimab and provide Vyera with a complimentary and novel product to bolster its pipeline of therapies for the treatment of infectious diseases.
“This agreement helps complete the strategic objective to further establish CytoDyn as a leader in efforts to enhance the lives of patients through target-specific medicine,” said Nader Pourhassan, Ph.D., CytoDyn’s President and Chief Executive Officer. “Vyera’s focus on developing therapies for patients living with serious and neglected diseases make them an ideal partner for this collaboration. We are excited to work with Vyera to leverage their platforms and capabilities to potentially offer a more effective treatment option for this HIV population.”
Averill L. Powers, Chief Executive Officer of Phoenixus AG, Vyera’s parent company, noted: “Vyera’s collaboration with CytoDyn demonstrates our commitment to address the needs of significant patient populations across our group companies generally and, in particular, a new level of our commitment to supporting patients living with HIV.”
Date Open High Low Close* Adj Close** Volume
Dec 27, 2019 0.83 1.05 0.82 0.98 0.98 8,268,900
Dec 26, 2019 0.64 0.79 0.62 0.78 0.78 4,641,500
Dec 24, 2019 0.61 0.66 0.58 0.64 0.64 1,772,600
Dec 23, 2019 0.62 0.67 0.58 0.61 0.61 4,180,600
Dec 20, 2019 0.65 0.66 0.50 0.58 0.58 5,232,900
Dec 19, 2019 0.43 0.74 0.43 0.63 0.63 9,052,700
Dec 18, 2019 0.35 0.45 0.35 0.42 0.42 3,501,500
Dec 17, 2019 0.29 0.31 0.29 0.30 0.30 443,700
Dec 16, 2019 0.31 0.31 0.29 0.29 0.29 647,700
December 17, 2019 16:36 ET | Source: CytoDyn, Inc.
In exchange for the exclusive right to market and distribute leronlimab in the U.S. for HIV-related indications, Vyera will pay upfront and regulatory and sales-based milestone payments of up to $87.5 million, as well as a royalty of 50 percent on net sales. Vyera will also make an investment in CytoDyn of $4 million in the form of registered CytoDyn common stock
CytoDyn will maintain responsibility for the development and FDA approval of leronlimab for all HIV-related and other indications
VANCOUVER, Washington and NEW YORK, Dec. 17, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn”) and Vyera Pharmaceuticals, LLC (“Vyera”), today announced that they have entered into a Commercialization and License Agreement (CLA) and a related Supply Agreement to commercialize leronlimab (PRO 140) in the U.S. for the treatment of HIV.
Under the terms of the CLA, CytoDyn will maintain responsibility for the development and FDA approval of leronlimab for all HIV-related and other indications, while Vyera has been granted an exclusive license to market and distribute leronlimab in the U.S. for the treatment of HIV. In exchange for such exclusive license, Vyera has agreed to pay upfront and regulatory and sales-based milestone payments of up to $87.5 million, as well as a royalty of 50 percent on net sales. Vyera also agreed to make an investment in CytoDyn of $4 million in the form of registered CytoDyn common stock.
It is anticipated that these agreements will enable CytoDyn to leverage Vyera’s well-established commercial infrastructure and highly-experienced sales team for the launch and commercialization of leronlimab and provide Vyera with a complimentary and novel product to bolster its pipeline of therapies for the treatment of infectious diseases.
“This agreement helps complete the strategic objective to further establish CytoDyn as a leader in efforts to enhance the lives of patients through target-specific medicine,” said Nader Pourhassan, Ph.D., CytoDyn’s President and Chief Executive Officer. “Vyera’s focus on developing therapies for patients living with serious and neglected diseases make them an ideal partner for this collaboration. We are excited to work with Vyera to leverage their platforms and capabilities to potentially offer a more effective treatment option for this HIV population.”
Averill L. Powers, Chief Executive Officer of Phoenixus AG, Vyera’s parent company, noted: “Vyera’s collaboration with CytoDyn demonstrates our commitment to address the needs of significant patient populations across our group companies generally and, in particular, a new level of our commitment to supporting patients living with HIV.”
(1)
(0)